NEW HAVEN, Conn., June 30 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a development stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic resistant infections, announced today that Russell Greig, Ph.D., of SR One venture capital, has been appointed to the Company's Board of Directors. Rib-X's board now consists of eleven members.
"We are extremely pleased that Russell Greig has joined the Rib-X Board of Directors," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "Russell brings an impressive mix of both R&D and business development experience that will be crucial as the Company grows and continues to move products through the development pipeline."
Russell Greig is President of SR One, the venture capital arm of GlaxoSmithKline (GSK). Prior to joining SR One, he served as President of GSK's Pharmaceuticals International from 2003 to 2008, and also served on the GSK Corporate Executive Team. Dr. Greig originally joined GSK (then SmithKline & French) in 1980 in the Departments of Tumor and Cell Biology. In 1991, following the merger with Beecham, he was appointed Vice President, Project Management. From 1993 to 1996, he served as Vice President and Director of Advanced Technologies in Genetics with special responsibility for managing collaborations with The Institute of Genomic Research and Human Genome Sciences. In 1996 Dr. Greig joined SmithKline Beecham's European Pharmaceutical Operations as Vice President and Director of European Market Development, and was later appointed Managing Director and General Manager of SmithKline Beecham's UK Pharmaceuticals. Following the merger of SmithKline Beecham with Glaxo Wellcome in 2000, he returned to the United States as Senior Vice President for Worldwide Business Development.
Dr. Greig also serves on the boards of Genocea Biosciences and the Edinburgh BioQuarter Commerci
|SOURCE Rib-X Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved